Actual medication label and appearance may vary
Supplement
SLU-PP-332
Choose a treatment option
SLU-PP-332 is a novel small-molecule compound classified as an "exercise mimetic." It works as a pan-agonist for the Estrogen-Related Receptors (ERR\alpha, ERR\beta, and ERR\gamma), which are master regulators of energy metabolism. Unlike other weight-loss medications that suppress appetite, SLU-PP-332 "tricks" the body’s muscles into behaving as if they are undergoing endurance training.
Check eligibilitySLU-PP-332 is not FDA-approved to diagnose, treat, cure, or prevent any disease or illness.
Why it works
Key benefits
- Weight Management: Significant reduction in fat mass accumulation without affecting food intake. Enhanced Endurance: In animal models, SLU-PP-332 increased running distance by up to 70%. Insulin Sensitivity: Improvements in glucose homeostasis and metabolic flexibility. Organ Protection: Potential secondary benefits for kidney and liver health through reduced oxidative stress.
Based on preclinical research
Mechanism
How it works
SLU-PP-332 activates a genetic program typically triggered by aerobic exercise: Mitochondrial Biogenesis: It stimulates the production of new mitochondria (the cell's power plants), increasing the body's oxidative capacity. Fatty Acid Oxidation: It enhances the body’s ability to burn fat for fuel, even at rest. Metabolic Reprogramming: It shifts muscle fibers toward a "slow-twitch" oxidative type, which is more resistant to fatigue and more efficient at utilizing energy.
Frequently asked questions
FAQs
While SLU-PP-332 is often called a "fitness pill," it is not a substitute for exercise. Patients may notice improved stamina and "metabolic energy" within the first 2–3 weeks. Significant changes in body composition typically require 8–12 weeks of consistent use paired with a structured nutrition plan.
As an investigational compound, the full side-effect profile in humans is not yet known. Based on preclinical data and early reports: Preclinical Risks: Potential for cardiac hypertrophy or elevated liver enzymes at high doses. Reported Effects: Increased hunger (occasionally), mild headache, or transient muscle soreness. Metabolic: Possible hypoglycemia if used with other glucose-lowering agents.
Research & Studies
Evidence at a Glance
- 1.
Billon, C., et al. (2023). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics.
- 2.
Nasri, H. (2024). New hopes on “SLU-PP-332” as an effective agent for weight loss with indirect kidney protection efficacy. Journal of Renal Endocrinology.
- 3.
Zhang, et al. (2024). Novel approach improves heart failure outcomes in animal models: Targeting ERR receptors. Baylor College of Medicine.
Interested in SLU-PP-332?
Take a short assessment and a licensed provider will review if this treatment is right for you.
Clinical Guidance Disclaimer
The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.
Liability & Indemnification
By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.
Regulatory Status
Unless otherwise stated on the specific medication label, these treatments involve compounded substances that are not FDA-approved to diagnose, treat, cure, or prevent any disease.
Proprietary Rights & Use Restrictions
This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.